Immatics takes up the Spac baton
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
Immatics and Molmed become the subjects of very different deals
Two acquisitions of cell therapy companies could take them in almost opposite directions.
SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Zelluna joins the adoptive cell therapy chase
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
